Smart drug hunts down hidden leukemia cells
NCT ID NCT03441061
First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 4 times
Summary
This phase II trial tests inotuzumab ozogamicin, a drug that targets and kills leukemia cells carrying a specific marker (CD22). It enrolls 40 adults with B-cell acute lymphoblastic leukemia who are in remission but still have minimal residual disease (MRD) — tiny amounts of cancer that standard tests miss. The goal is to see if the drug can improve relapse-free survival and clear these hidden cells.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- inotuzumab ozogamicin (Besponsa)
- What this could lead to
- If successful, this could offer a targeted treatment option for leukemia patients with lingering disease after standard therapy, potentially delaying or preventing relapse.
- What could go wrong
- This is a small, early-phase trial (40 participants) with no control group, so results may not be conclusive. The drug can cause serious side effects like liver toxicity and infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can donor immune cells tame stem cell transplant risks?
- Can engineered immune cells outsmart resistant blood cancers?
- A simple blood draw could spare kids with leukemia from painful bone marrow tests